Ipca Laboratories has decided to sell its drug intermediates and active pharmaceutical ingredients (APIs) manufacturing unit located in Ankleshwar, Gujarat, to M/s. Suleshvari Pharma Private Ltd. The sale, which includes all rights and interests in the leasehold land and related assets, will be executed on a slump sale basis for a consideration of ₹22.15 crores. This decision is part of the company’s strategy to optimize operations and reduce manufacturing units.
Strategic Divestment
Ipca Laboratories has approved the sale and transfer of its drug intermediates and active pharmaceutical ingredients (APIs) manufacturing unit, situated at GIDC Industrial Estate, Ankleshwar. This move is aligned with the company’s operational strategy to reduce the number of manufacturing units and minimize operational costs. The decision was made during the Board of Directors meeting held on October 17, 2025.
Transaction Details
The manufacturing unit is being sold to M/s. Suleshvari Pharma Private Ltd. on a slump sale basis, subject to necessary approvals. The sale encompasses all rights, title, and interest in the leasehold land, factory buildings, plant and machineries, employees, and business related to the facility. The total consideration for the sale is ₹22.15 crores.
Asset Details and Impact
The manufacturing unit is located at leasehold Plot Nos. 4722, 4723, 4724, 4730, 4731, and 4732 at GIDC Industrial Estate, Ankleshwar – 393 002 (Gujarat). Ipca Laboratories has stated that the sale of this manufacturing unit is not expected to have a material impact on the Company’s business and financials.
Timeline and Rationale
The transaction is expected to be completed on or before December 31, 2025, or another mutually agreed date, subject to necessary consent from GIDC for the transfer of leasehold rights. The rationale behind the sale is to optimize manufacturing facilities and reduce the number of smaller manufacturing facilities, thereby reducing overall administrative and other operating costs.
About the Buyer
The buyer, M/s. Suleshvari Pharma Pvt. Ltd., is engaged in the business of development, manufacture, distribution, and sale of drug intermediates and bulk drugs. They are not part of the promoter/promoter group of Ipca Laboratories and the transaction is not considered a related party transaction.
Source: BSE
